TY - JOUR
T1 - 3D PCL/collagen nanofibrous medical dressing for one-time treatment of diabetic foot ulcers
AU - Chang, Ting
AU - Yin, Huiyi
AU - Yu, Xi
AU - Wang, Lihuan
AU - Fan, Longfei
AU - Xin, John H.
AU - Yu, Hui
N1 - Funding Information:
This work was financially supported by the Natural Science Foundation of Guangdong Province , China ( 2019A1515011769 ), the Guangdong Science and Technology Major Special Fund , China (No. 2019-252 ), the Foundation of Higher Education of Guangdong , China (No. 2020ZDZX2038 ), the Science Foundation for Young Research Group of Wuyi University (No. 2019td08 ) and the Guangdong/Hong Kong Joint Foundation of Wuyi University (No. 2019WGALH11 ), the Guangdong Basic and Applied Basic Research Foundation ( 2021A1515110510 ), and the Project of Educational Commission of Guangdong Province , China ( 2021KQNCX102 ).
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/6
Y1 - 2022/6
N2 - Nanofibrous dressings exhibit high specific surface areas, good histocompatibility, enhanced wound healing, and reduced inflammation, which have broad technological implications for treating diabetic foot ulcers (DFUs). However, current nanofibrous dressings still suffer from high resistance to cell infiltration and multiple dressing changes. In this study, polycaprolactone (PCL) and collagen were adopted as electrospinning materials to prepare a 3D PCL/Collagen (PC) nanofibrous dressing (3D-PC) using aqueous phase fibre reassembly technology. The matrix metalloproteinases (MMPs) inhibitor doxycycline hyclate (DCH)-loaded halloysite nanotubes (HNTs) (DCH@HNTs) and antibacterial agent cephalexin (CEX) were loaded onto the dressing to prepare a multifunctional 3D drug-loaded PCL/Collagen nanofibrous dressing to promote DFU wound healing. The obtained 3D nanofibrous dressing exhibited high water absorption capacity and swelling capacity. It showed good antibacterial activity against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) in vitro antibacterial test. In addition, the 3D nanofibrous dressing demonstrated good biocompatibility. It could significantly reduce the frequency of dressing changes and improve the healing of DFU wounds compared with the conventional multiple dressing changes method, suggesting a potential candidate for healing diabetic wounds.
AB - Nanofibrous dressings exhibit high specific surface areas, good histocompatibility, enhanced wound healing, and reduced inflammation, which have broad technological implications for treating diabetic foot ulcers (DFUs). However, current nanofibrous dressings still suffer from high resistance to cell infiltration and multiple dressing changes. In this study, polycaprolactone (PCL) and collagen were adopted as electrospinning materials to prepare a 3D PCL/Collagen (PC) nanofibrous dressing (3D-PC) using aqueous phase fibre reassembly technology. The matrix metalloproteinases (MMPs) inhibitor doxycycline hyclate (DCH)-loaded halloysite nanotubes (HNTs) (DCH@HNTs) and antibacterial agent cephalexin (CEX) were loaded onto the dressing to prepare a multifunctional 3D drug-loaded PCL/Collagen nanofibrous dressing to promote DFU wound healing. The obtained 3D nanofibrous dressing exhibited high water absorption capacity and swelling capacity. It showed good antibacterial activity against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) in vitro antibacterial test. In addition, the 3D nanofibrous dressing demonstrated good biocompatibility. It could significantly reduce the frequency of dressing changes and improve the healing of DFU wounds compared with the conventional multiple dressing changes method, suggesting a potential candidate for healing diabetic wounds.
KW - Collagen
KW - Diabetic foot ulcer
KW - Nanofibrous medical dressing
KW - One-time dressing change
KW - Polycaprolactone
UR - http://www.scopus.com/inward/record.url?scp=85127033641&partnerID=8YFLogxK
U2 - 10.1016/j.colsurfb.2022.112480
DO - 10.1016/j.colsurfb.2022.112480
M3 - Journal article
C2 - 35358884
AN - SCOPUS:85127033641
SN - 0927-7765
VL - 214
JO - Colloids and Surfaces B: Biointerfaces
JF - Colloids and Surfaces B: Biointerfaces
M1 - 112480
ER -